NVS: 诺华制药

NVS新闻

• 12:40 Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
• 15:13 FDA授予诺华Rapcabtagene Autoleucel用于治疗特发性炎性肌病的孤儿药资格认定
• 15:13 FDA Grants Orphan Drug Designation To Novartis’ Rapcabtagene Autoleucel For Treatment Of Idiopathic Inflammatory Myopathies
• 14:00 Novartis: The Sell-Off Creates An Attractive Entry Point (NYSE:NVS)
• 12:00 Why A Biotech M&A Wave May Hit This Winter
• 14:03 Cancer Stocks to Consider as Oncology Innovation Accelerates
• 15:19 NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
• 13:40 Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
• 18:28 FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
• 18:28 FDA批准诺华的Rhapsido作为首个慢性摩擦性荨麻疹治疗药物
• 15:54 Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism
• 15:21 Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
• 13:22 Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
• 14:00 Top 25 Attractive Dividend Stocks For October 2026
• 14:27 Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
• 19:02 A Federal Judge In Manhattan Ruled For Novartis On Wednesday Against Allegations That It Misused One Of Its Patents To Maintain Its Exclusivity On Its Blockbuster Heart-Failure Drug Entresto
• 19:02 曼哈顿的一名联邦法官周三裁定支持诺华公司，驳回了指控其滥用专利以维持其心力衰竭明星药物Entresto的独家性的指控。
• 16:13 Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
• 16:25 Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
• 16:25 赛尔德克斯准备提交2027年慢性皮肤病的FDA申请
• 14:07 Amgen Boasts Success In Sjogren's; Shares Charge Ahead
• 21:14 Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
• 15:57 NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
• 13:45 Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash